|
Improved bioavailability with Megace ES AIDS patients experiencing loss of appetite and unintended weight loss may not have the desire to eat. Megace ES offers improved bioavailability in the unfed condition vs. original formula Megace®.*†1  • Megace ES offers improved bioavailability in the unfed condition vs. original formula Megace*†1 • There was comparable bioavailability between Megace ES and original
formula Megace in the
*Megestrol acetate oral suspension. †Clinical significance unknown. Megace ES has improved absorption over original formula Megace in people who have not eaten (the unfed state). For people who have eaten (fed condition), Megace ES and original formula Megace have similar absorption into the body. The fed condition is achieved by subjects eating a high-calorie (800-1000 calories) and high-fat (approximately 50% of total calories) meal.16
|
Indication
Megace ES (megestrol acetate) is a concentrated suspension indicated for the treatment of anorexia (loss of appetite),
cachexia (severe malnutrition), or an unexplained, significant weight loss in people with a diagnosis of AIDS.1
Megace ES is available by Prescription Only. For full Prescribing Information, click here.
*Adverse events greater than placebo derived from the comprehensive adverse events table (≥5%) in Megace ES and megestrol acetate oral suspension prescribing information.
NanoCrystal® is a registered trade mark of Elan Pharma International Limited, Ireland.